Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Bullish +75

Bristol Myers' Growth Portfolio Just Overtook The Legacy One

AI-generated analysis

📉 Bristol-Myers Squibb (BMY) is currently viewed by the market as a "melting ice cube" due to fears that its legacy revenue stream is collapsing.

📊 The company's Growth Portfolio has officially surpassed its Legacy Portfolio in terms of revenue for Q1 2026.

💊 Four near-term pipeline catalysts are identified: iberdomide, mezigdomide, milvexian, and Cobenfy.

⏳ These four new drugs could potentially force a stock re-rating within the next seven months.

📈 Even under bearish consensus forecasts, a Discounted Cash Flow (DCF) model supports a valuation of $68.5 per share.

💰 This supported valuation represents approximately 20% upside from current price levels with downside protection.

📉 BMY is trading at a 9x forward earnings multiple and offers a dividend yield of 4.35%.

🛡️ The investment thesis suggests the stock provides free pipeline optionality rather than facing a cliff after Eliquis.

🧬 Revlimid has fallen off its peak, leading to market concerns that Eliquis will be the next major revenue driver.

📊 The author utilizes a data analytics and SQL background to analyze market trends and patterns for this article.

🤝 The author discloses no current stock positions or plans to initiate positions in the mentioned companies within 72 hours.

⚠️ Seeking Alpha notes that past performance does not guarantee future results and this is not investment advice.

Bullish Signals
  • Bristol Myers Squibb's Growth Portfolio revenues surpassed Legacy revenues in Q1 2026, signaling a successful transition away from reliance on Revlimid.
  • The company has four near-term pipeline catalysts including iberdomide, mezigdomide, milvexian, and Cobenfy that could drive a stock re-rating within seven months.
  • Even using bearish consensus forecasts, the discounted cash flow (DCF) model supports a $68.5/share valuation, which is approximately 20% above current levels.
  • BMY offers downside protection with a 9x forward earnings multiple and a 4.35% dividend yield.
  • The company provides free pipeline optionality and a financial bridge beyond its key drug Eliquis, rather than facing a cliff.
Risk Factors
  • The market narrative has been dominated for three years by the fear that Revlimid fell off a cliff, creating a bearish sentiment that Eliquis will be the next major revenue driver.
  • Despite the growth portfolio surpassing legacy revenues in Q1 2026, the article explicitly states the stock is 'mispriced as a melting ice cube', indicating significant underlying fragility and potential value erosion.
  • The valuation support of $68.5/share relies on bearish consensus forecasts, suggesting that even under pessimistic assumptions, the market may be undervaluing the risk of further declines.
  • The company's future beyond Eliquis is described as a 'bridge' rather than a 'cliff', implying uncertainty and potential instability in long-term revenue sustainability.
  • The reliance on four near-term catalysts (iberdomide, mezigdomide, milvexian, and Cobenfy) to force a re-rating within seven months suggests the current business model lacks sufficient organic growth drivers without these specific bets.
Full Analysis
Bristol-Myers Squibb's growth portfolio has surpassed its legacy business in revenue for the first time during Q1 2026, challenging the prevailing market narrative that the company is a "melting ice cube" solely reliant on declining Revlimid and Eliquis sales. The article identifies four specific near-term catalysts within the pipeline—iberdomide, mezigdomide, milvexian, and Cobenfy—that could drive a stock re-rating within seven months of the report's publication. Valuation analysis suggests the stock is mispriced relative to its fundamentals; even under bearish consensus forecasts, a discounted cash flow (DCF) model supports a target price of $68.5 per share, which represents approximately 20% upside from current levels with downside protection. The company currently trades at a 9x forward earnings multiple and offers a 4.35% dividend yield, positioning it as a bridge to future growth rather than facing an immediate cliff in revenue generation.